Sava Raises $36M Series B and Lands Ascensia Glucose-Sensor Deal

Sava Technologies has raised a $36 million Series B led by Ascensia Diabetes Care, pairing fresh capital with a European commercialization and distribution agreement for Sava’s investigational glucose microsensor.

Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments and Pentland Ventures also participated. The London company said the round brings its total funding to $68 million. It did not disclose a valuation.

The structure of the announcement is more important than the round size alone. Ascensia is both the lead investor and the prospective route to market. Its CONTOUR blood-glucose products are sold in more than 90 countries, and it has direct commercial organizations in 29 markets.

Subject to regulatory approval, Ascensia will lead Sava’s initial European launch.

A shorter sensor in an incumbent market

Sava is developing a wearable platform that measures molecules in interstitial fluid just beneath the skin. Its first product is a continuous glucose monitor, or CGM.

The company says its microsensor is roughly ten times shorter than the filament used in conventional CGMs. A shorter sensor could reduce disruption to the skin and improve comfort, but Sava still needs to demonstrate accuracy, durability and manufacturability at commercial scale.

Sava intends the same platform to measure additional biomarkers over time. That broader ambition is strategically attractive, yet glucose provides the clearest initial market because reimbursement pathways, clinical workflows and consumer demand already exist.

The challenge is competition. Abbott and Dexcom dominate continuous glucose monitoring, while Medtronic and Senseonics offer alternative systems. Entrants therefore need more than a technically elegant sensor: they need regulatory clearance, scalable manufacturing, payer access and trusted distribution.

The Ascensia deal addresses part of that commercialization stack.

What the $36 million funds

Sava plans to use the Series B for manufacturing scale-up and commercial readiness ahead of a pivotal clinical study.

The company is targeting European CE approval for non-adjunctive use within 18 to 24 months. Non-adjunctive clearance would allow users to make insulin-dosing decisions from the device without routine confirmatory finger-stick testing.

That is a meaningful regulatory threshold. Without it, the product would supplement conventional testing rather than replace it for critical treatment decisions.

Sava’s sensor remains investigational. The company states that its performance has not been fully determined and that it has not received authorization from the UK’s Medicines and Healthcare products Regulatory Agency or the US Food and Drug Administration.

Investors should therefore treat the target timeline as a plan, not a guaranteed launch date.

Why Ascensia changes the risk profile

Medical-device startups often raise capital years before solving distribution. Sava is approaching the sequence differently by aligning its Series B with a commercialization partner that already serves diabetes patients, clinicians and payers.

Ascensia brings a recognized diabetes brand and a European sales footprint. It also gives the lead investor a strategic reason to help Sava reach market, beyond the financial return on the equity.

That alignment can reduce go-to-market risk, but it also creates dependencies. The economics and exclusivity of the distribution agreement were not disclosed. Sava’s European performance may depend heavily on Ascensia’s launch priorities, reimbursement strategy and ability to position a new CGM against larger incumbents.

The partnership is therefore both an asset and a concentration risk.

Funding history and investor signal

Sava was founded in 2019 and previously announced an $8 million seed round and a $19 million Series A. Balderton and Pentland led the Series A, with Norrsken, JamJar and other investors participating.

Their return in the Series B indicates continued support after early clinical work. Ascensia’s decision to lead adds industry validation at the point where Sava must shift from technical development to regulated manufacturing and commercialization.

Sava says around 12 million people currently use CGMs, compared with 589 million adults living with diabetes. Those figures describe a large theoretical gap, but the serviceable market will depend on diagnosis rates, reimbursement, device pricing and local clinical practice.

What to watch next

Four milestones will determine whether this financing creates a viable challenger:

1. the design and results of Sava’s pivotal clinical study;
2. manufacturing yield and quality-system readiness;
3. the timing and scope of CE approval;
4. the commercial terms and rollout performance of the Ascensia partnership.

Evidence on sensor accuracy across ten days, different patient populations and real-world conditions will matter more than comfort claims alone. So will pricing: a smaller sensor is not enough if the total system cannot compete with established CGMs.

Sava has now assembled capital, a strategic lead investor and a plausible European distribution channel. The next phase is less about proving that microsensing works in principle and more about proving that it can clear regulators, scale economically and win trust in a market dominated by entrenched platforms.